The Experts below are selected from a list of 3483 Experts worldwide ranked by ideXlab platform
Aaron B Caughey - One of the best experts on this subject based on the ideXlab platform.
-
how should costs and cost effectiveness be considered in Prenatal genetic testing
Seminars in Perinatology, 2018Co-Authors: Teresa N Sparks, Aaron B CaugheyAbstract:Abstract In January 2017, a group of experts in Prenatal Genetics attended a workshop at the Society of Maternal-Fetal Medicine meeting to review the evidence behind the costs and cost-effectiveness of Prenatal genetic testing. Over the past decade, Prenatal genetic testing options have dramatically expanded to include additional options with cell-free DNA (cfDNA) screening, as well as increased diagnostic abilities through chromosomal microarray analysis (CMA), gene panels, whole exome sequencing, and other tests. With these expanding technologies, it is important to consider the options available as well as the cost effectiveness of their use. Other important considerations are the effects of movements toward value-based health care; the role of professional societies, commercial laboratories, and insurers; disparities that exist in Prenatal genetic testing; and outcomes for both patients and health care systems. Workshop participants identified key areas of research to advance our understanding of the costs and cost-effectiveness of Prenatal genetic testing, which include (1) understanding the short- and long-term costs to patients and to health care systems with Prenatal genetic tests; (2) elucidating the short- and long-term health outcomes for parents and children that are important to consider when comparing one testing strategy to another; (3) understanding the value underlying Prenatal genetic testing to individuals and health care systems; and (4) identifying disparities in Prenatal genetic testing, reasons for these disparities, and how to minimize them.
Teresa N Sparks - One of the best experts on this subject based on the ideXlab platform.
-
how should costs and cost effectiveness be considered in Prenatal genetic testing
Seminars in Perinatology, 2018Co-Authors: Teresa N Sparks, Aaron B CaugheyAbstract:Abstract In January 2017, a group of experts in Prenatal Genetics attended a workshop at the Society of Maternal-Fetal Medicine meeting to review the evidence behind the costs and cost-effectiveness of Prenatal genetic testing. Over the past decade, Prenatal genetic testing options have dramatically expanded to include additional options with cell-free DNA (cfDNA) screening, as well as increased diagnostic abilities through chromosomal microarray analysis (CMA), gene panels, whole exome sequencing, and other tests. With these expanding technologies, it is important to consider the options available as well as the cost effectiveness of their use. Other important considerations are the effects of movements toward value-based health care; the role of professional societies, commercial laboratories, and insurers; disparities that exist in Prenatal genetic testing; and outcomes for both patients and health care systems. Workshop participants identified key areas of research to advance our understanding of the costs and cost-effectiveness of Prenatal genetic testing, which include (1) understanding the short- and long-term costs to patients and to health care systems with Prenatal genetic tests; (2) elucidating the short- and long-term health outcomes for parents and children that are important to consider when comparing one testing strategy to another; (3) understanding the value underlying Prenatal genetic testing to individuals and health care systems; and (4) identifying disparities in Prenatal genetic testing, reasons for these disparities, and how to minimize them.
Judith Tsipis - One of the best experts on this subject based on the ideXlab platform.
-
NIPT: Current utilization and implications for the future of Prenatal genetic counseling
Prenatal Diagnosis, 2014Co-Authors: Amanda Buchanan, Amy Sachs, Tomi Toler, Judith TsipisAbstract:BACKGROUND: Non-invasive Prenatal testing (NIPT) for select fetal trisomies became clinically available in 2011. When it was introduced, there were no recommendations from the major governing bodies in Prenatal Genetics regarding its incorporation. PURPOSE: We sought to determine how genetic counselors have incorporated NIPT into clinical practice and how NIPT has changed the informed consent process. METHODS: We distributed an anonymous, online survey to National Society of Genetic Counselors (NSGC) members in October 2012. RESULTS: There were 181 respondents who indicated they incorporated NIPT into their practice with the majority (94.1%) offering it to patients with high risk pregnancies. Of the respondents, 45.1% indicated that there should be a separate informed consent form for NIPT. Respondents indicated that a discussion about NIPT with a patient should highlight that it is a screening test, the detection rate is superior to that of maternal serum screening, it screens for specific conditions, and a positive NIPT result should be confirmed with a diagnostic test. CONCLUSION: Following data collection, the American Congress of Obstetricians and Gynecologists, the American College of Medical Genetics, and NSGC released practice guidelines surrounding NIPT. Our results demonstrate that most genetic counselors have been offering NIPT consistent with these guidelines. © 2014 John Wiley & Sons, Ltd.
Amanda Buchanan - One of the best experts on this subject based on the ideXlab platform.
-
NIPT: Current utilization and implications for the future of Prenatal genetic counseling
Prenatal Diagnosis, 2014Co-Authors: Amanda Buchanan, Amy Sachs, Tomi Toler, Judith TsipisAbstract:BACKGROUND: Non-invasive Prenatal testing (NIPT) for select fetal trisomies became clinically available in 2011. When it was introduced, there were no recommendations from the major governing bodies in Prenatal Genetics regarding its incorporation. PURPOSE: We sought to determine how genetic counselors have incorporated NIPT into clinical practice and how NIPT has changed the informed consent process. METHODS: We distributed an anonymous, online survey to National Society of Genetic Counselors (NSGC) members in October 2012. RESULTS: There were 181 respondents who indicated they incorporated NIPT into their practice with the majority (94.1%) offering it to patients with high risk pregnancies. Of the respondents, 45.1% indicated that there should be a separate informed consent form for NIPT. Respondents indicated that a discussion about NIPT with a patient should highlight that it is a screening test, the detection rate is superior to that of maternal serum screening, it screens for specific conditions, and a positive NIPT result should be confirmed with a diagnostic test. CONCLUSION: Following data collection, the American Congress of Obstetricians and Gynecologists, the American College of Medical Genetics, and NSGC released practice guidelines surrounding NIPT. Our results demonstrate that most genetic counselors have been offering NIPT consistent with these guidelines. © 2014 John Wiley & Sons, Ltd.
Amy Sachs - One of the best experts on this subject based on the ideXlab platform.
-
NIPT: Current utilization and implications for the future of Prenatal genetic counseling
Prenatal Diagnosis, 2014Co-Authors: Amanda Buchanan, Amy Sachs, Tomi Toler, Judith TsipisAbstract:BACKGROUND: Non-invasive Prenatal testing (NIPT) for select fetal trisomies became clinically available in 2011. When it was introduced, there were no recommendations from the major governing bodies in Prenatal Genetics regarding its incorporation. PURPOSE: We sought to determine how genetic counselors have incorporated NIPT into clinical practice and how NIPT has changed the informed consent process. METHODS: We distributed an anonymous, online survey to National Society of Genetic Counselors (NSGC) members in October 2012. RESULTS: There were 181 respondents who indicated they incorporated NIPT into their practice with the majority (94.1%) offering it to patients with high risk pregnancies. Of the respondents, 45.1% indicated that there should be a separate informed consent form for NIPT. Respondents indicated that a discussion about NIPT with a patient should highlight that it is a screening test, the detection rate is superior to that of maternal serum screening, it screens for specific conditions, and a positive NIPT result should be confirmed with a diagnostic test. CONCLUSION: Following data collection, the American Congress of Obstetricians and Gynecologists, the American College of Medical Genetics, and NSGC released practice guidelines surrounding NIPT. Our results demonstrate that most genetic counselors have been offering NIPT consistent with these guidelines. © 2014 John Wiley & Sons, Ltd.